Production (Stage)
LAVA Therapeutics N.V.
LVTX
$1.32
$0.021.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 4.99M | -- | -- | 6.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 4.99M | -- | -- | 6.99M |
| Cost of Revenue | -- | 24.55M | -- | -- | -- |
| Gross Profit | -- | -19.56M | -- | -- | 6.99M |
| SG&A Expenses | 3.43M | 4.48M | 2.79M | 3.03M | 3.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.59M | 8.19M | 11.29M | 9.36M | 9.03M |
| Operating Income | -7.59M | -3.20M | -11.29M | -9.36M | -2.04M |
| Income Before Tax | -3.25M | -3.59M | -12.20M | -8.21M | -539.00K |
| Income Tax Expenses | 225.00K | 380.00K | 96.00K | 85.00K | 69.00K |
| Earnings from Continuing Operations | -3.48M | -3.97M | -12.30M | -8.30M | -608.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.48M | -3.97M | -12.30M | -8.30M | -608.00K |
| EBIT | -7.59M | -3.20M | -11.29M | -9.36M | -2.04M |
| EBITDA | -7.48M | -3.11M | -11.17M | -9.24M | -1.89M |
| EPS Basic | -0.13 | -0.15 | -0.46 | -0.31 | -0.02 |
| Normalized Basic EPS | -0.20 | 0.01 | -0.28 | -0.19 | -0.01 |
| EPS Diluted | -0.13 | -0.15 | -0.46 | -0.31 | -0.02 |
| Normalized Diluted EPS | -0.20 | 0.01 | -0.28 | -0.19 | -0.01 |
| Average Basic Shares Outstanding | 26.89M | 26.87M | 26.85M | 26.82M | 26.79M |
| Average Diluted Shares Outstanding | 26.89M | 26.87M | 26.85M | 26.82M | 26.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |